Background and study aim: Hepatic steatosis in hepatitis C virus (HCV) infected patients has been shown to enhance the progression of liver fibrosis and decrease the response to antiviral therapy. The current study is designed to investigate the impact of hepatic steatosis on the outcome of pegylated interferon and ribavirin combination therapy in patients with chronic hepatitis C genotype 4. Patients and Methods: A total number of 200 patients were selected from 270 patients who were referred to HCV Treatment Unit of New Mansoura General Hospital from February 2012 to August 2013 after taking an informed consent. They were 129 males and 71 females, their ages ranged from 25 to 55 years (mean value, 35.5±15.2). They had proven chronic hepatitis C virus based on history of exposure, clinical manifestations, positive anti-HCV antibody, positive HCV viremia, and liver biopsy findings suggestive of chronic hepatitis C.
Results: Group I: included 100 patients (70 men and 30 women; mean age of 42.912 years) without liver steatosis. Group II: included 100 patients (59 men and 41 women; mean age of 45.2311 years) with liver steatosis. In terms of steatosis grading using the NAS and METAVIR scoring systems, 50% had no staetosis while 8.5% had mild staetosis, 18.5% had moderate steatosis and 23% had severe steatosis. Body mass index of patients receiving interferon is significant between both groups. Hepatomegaly shows significant values between both groups. Platelets count, ALT, AST, S.Cholesterol & S.Triglycerides levels has statistically significant differences between group I (non steatotic) and group II (steatotic). There is statistically significant difference between both groups on necro-inflamatory activity grades. High statistical significance difference between grading of steatosis and Necro-inflammation. Statistical significance difference between grading of steatosis and fibrosis stages. Statistical significance difference between both groups at SVR and Steatosis has a negative effect on SVR by comparison to non steatotic group. High degree of hepatic steatosis has a negative impact on pagylated interferon and ribavirin therapy in chronic HCV genotype 4 minimizing sustained virologic response rates.
INTRODUCTION
The incidence of hepatitis C virus (HCV) infections is falling in some countries, however the burden of the disease in Egypt continues to rise. It has been estimated that, by 2030, HCV will cause substantially higher morbidity and mortality than HIV. Chronic Hepatitis C (CHC) occurs in 70% to 80% of those who contract the virus, 20% of whom will progress to cirrhosis within 2-3 decades; a quarter of these will develop decompensated liver disease, hepato-cellular carcinoma (HCC) and will need liver transplantation. A recent study has shown that HCV infected persons have three times higher death rates than those of age-matched general population [1] .
In patients with chronic HCV infection, steatosis is attributable to a variable combination of the mechanisms considered to play a role in the pathogenesis of NAFLD; insulin resistance in the obese and in the lean subject along with a direct effect of HCV on hepatic lipid metabolism that leads to triglyceride accumulation through inhibition of export proteins that are required for very low density lipoprotein (VLDL) assembly and secretion [2] .
Hepatic steatosis resulting from host metabolic factors or via direct viral effect has been associated with increased fibrosis, regardless of genotype. Worsening hepatic steatosis also is associated with increased periportal necrosis, hepatocyte apoptosis, and fibrosis progression [3] .
Leptin also may mediate fibrogenesis. This satiety hormone has been shown to be profibrogenic and up-regulation of leptin signaling may lead to fibrosis progression. In CHC genotype 1 patients there appears to be a correlation between serum leptin levels, steatosis, and fibrosis [4] .
Steatosis seems to reduce the likelihood of obtaining sustained virological response (SVR) from HCV medications at least in people with HCV non-3 type, the impact of steatosis on SVR in genotype 3 is less clear [5] .
The risk of non-response to antiviral therapy was increased 2-fold if significant steatosis or steatohepatitis (SH) were present on biopsy. Furthermore, there is a significant difference in overall SVR between groups. It is noteworthy that the effect of steatosis/SH on SVR was greatest in the genotype 2 or 3 patients [6] .
It is become clear that there is direct viral mechanisms involved in the development of steatosis in people infected with HCV genotype 3, although in genotype other than 3 other cofactors such as high BMI, heavy alcohol intake, elevated blood lipids, glucose intolerance and diabetes greatly promotes the development of steatosis [5] .
Besides obesity, type 2 diabetes mellitus (DM) and hypertriglyceridemia have also been associated with hepatic steatosis in patients with non-alcoholic fatty liver disease [7] .
Aim of the work:
The current study is designed to investigate the impact of hepatic steatosis on the outcome of pegylated interferon and ribavirin combination therapy in patients with chronic hepatitis C. 
PATIENTS AND METHODS

RESULTS
Chronic HCV genotype 4 is associated with hepatic steatosis which is mostly metabolic associated with elevated BMI, triglycerides and cholesterol levels.
-Body mass index of patients has statistical significant between both groups as shown in triglycerides levels has statistically significant difference between group I (non steatotic) and group II (steatotic) group as shown in Table  ( 2). -Statistical significance between both groups on necroinflamatory activity grades as shown in Table ( 3). -High statistical significance between grading of steatosis and necro-inflammation as shown in Table ( 4) and Figure ( 2). -Statistical significance between grading of steatosis and fibrosis stages as shown in Table  ( 4) and Figure ( 3). -Statistical significance between both groups at SVR and steatosis has a negative effect on SVR by comparison to non steatotic group as shown in Table (5). -High degree of hepatic steatosis has a negative impact on pagylated interferon and ribavirin therapy in chronic HCV genotype 4 minimizing sustained virologic response rates. 
DISCUSSION
In the current work, there were a significant corelation between BMI and steatosis so it means that steatosis in HCV genotype 4 is metabolic as shown in table (1) and this is in agreement with El-Zayadi et al. [8] who concluded that steatosis was independently associated with diabetes mellitus as well as increased BMI. These findings support the proposed causal relation to metabolic factors rather than to cytopathic effect of HCV genotype 4.
Our results revealed statistical significance relation between levels of cholesterol and triglycerides and presence of steatosis as shown in Table ( 2) and Figure (1) . Also our findings are in accordance with Sanyal et al. [9] , who reported that the presence of steatosis in HCV genotype 4 infected patients was strongly associated with obesity, diabetes mellitus and abnormal lipid profile.
Our results revealed statistical significant relation concerning AST & ALT levels with patients of group I compared with those of group II (P<0.05) as shown in Table ( 2) and this is in agreement with Minerva [10] mentioned that liver enzymes levels are raised in case of steatosis.
In our series, there was no significant correlation between steatosis and viral load as shown in table (2) and this is an agreement with El-Zayadi et al. [8] who concluded that the presence of steatosis in 55.6%, 52.6%, 56.3% and 60% of genotype 4 patients with very low, low, moderate and severe viral load respectively. This may reflect the absence of association between viral load and steatosis in genotype 4 patients as the proportion of patients with steatosis did not show significant increase with the increase in viral load.
In the present study, there was a significant correlation between stage of fibrosis and steatosis level as shown in Table ( 4) and Figure ( 3) and this in accordance with Lonardo et al. [11] who revealed that steatosis is a definite cofactor of chronic hepatitis C which accelerates the progression to end-stage liver disease.
In our study there is a high significant correlation between steatosis and necro-inflamtion as shown in Table ( 4) and Figure ( 2) and this in accordance with Lonardo et al. [12] who declared that Presence of steatosis was also correlated with necro-inflammatory activity in nonalcoholic steatohepatitis as well as chronic hepatitis C.
Our study shows that steatosis has a negative effect on SVR by comparison to non steatotic group as shown in Table ( 5) and Figure (4) and this is in accordance with Fried et al. [13] who concluded that advanced hepatic fibrosis is a negative predictor of SVR to therapy Everson et al. [13] .
Our study shows that there is a good correlation between direct fibrosis progression rate and histological activity because fibrosis might be a result of the necro-inflammatory activity as shown in Table (4,5 ) and this accordance with Mendes et al. [14] who found good correlation between direct fibrosis progression rate and histological activity because fibrosis might be a result of the necro-inflammatory activity.
CONCLUSION
There is strong association between the degree of liver steatosis and fibrosis staging. Although patients with high grading scores tended to have more steatosis; there is a statistical significant correlation between the degree of steatosis and the necro-inflammatory grade Hepatic steatosis and obesity were predictors of poor response to pegylated IFN and ribavirin therapy in CHC genotype 4.So reduction of the weight before treatment is an important to improve sustained response rates. The evaluation of hepatic steatosis is not only useful for prediction of treatment outcome, but also important for investigation of new approaches toward overcoming the IFN resistance in patients with chronic hepatitis C.
